Defining HTA in Europe

In this ISSUE

The Pharm Exec Podcast: The Impact of Robotics in Pharma

China Expedites Anticancer Drug Price Reduction

Quality Failures at Foreign Manufacturers Prompt FDA Warnings and Recalls

Top Story

Who Knows What HTA Really Is?

A recently announced collaboration between EUnetHTA, WHO, and ISPOR brings home the fact that there is still no real agreement on a definition of HTA, writes Reflector
… /Read more/

A panel discussion with insights from emerging biopharma executives
Wednesday, October 3, 2018 at 11am EDT

China

The TKI Lung Cancer Market in China

Tyrosine-kinase inhibitors (TKIs) are gradually becoming the most popular option for lung cancer treatment in China. Jin Zhang reports
… /Read more/

Leverage Your Data to Meet Rising Expectations within Life Sciences
Thursday, September 13, 2018 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST

Calendar

/ September 13–14: Global Risk Based Monitoring /

London, UK

/ October 15–17: 28^th Annual Sharing Conference: Compliance /

National Harbor, MD

/ November 14–15: Commercial Data Insights 2018 /

Philadelphia, PA

/ November 14–15: 5^th Annual Global Compliance Congress for Life Sciences /

London, UK

/ November 28–29: Compliant Patient Support Programs Summit /

Philadelphia, PA

/ December 4–5: Managed Markets Compliance Congress 2018 /

Philadelphia, PA

Interview

The Patient-Engagement Quest: A Conversation with DIA's Barbara Lopez Kunz

DIA's global chief executive talks about the current trajectory of patient-centric product development and the need to establish common pathways and metrics to best harness its potential in everyday practice
… /Read more/

Interview

Close to the Action: Dr. José Luis Cabero, AELIX Therapeutics

Pharm Exec talks to AELIX Therapeutics' CEO Dr. José Luis Cabero about how the career and country shift he made a decade ago have motivated and sustained a new direction in his career
… /Read More/

Special Report

Emerging Collaboration in EU Drug Pricing and Reimbursement: A Beneluxa Case Study

Using the joint price negotiations developed across Europe as the Beneluxa Initiative on Pharmaceutical Policy as a case study, Maude Schmidt and Giovanni Saldutti explore the implications of such intergovernmental initiatives
… /Read More/

Industry update

// Tanja Bosshard Becker was appointed as Partner at Executive Insight (Zurich, Switzerland). // Tillotts Pharma (Rheinfelden, Switzerland) and the Zeria Group appointed Dr. Karima Boubekeur as the Group's new Global Head of Innovation. // Probiodrug (Halle, Germany) appointed Dr. Michael Schaeffer as Executive Vice President of Business and Strategy. // UK-headquartered healthcare services provider Ashfield appointed Pierre Van Weperen as Managing Director for Commercial and Patient Solutions, UK. // Vertex Pharmaceuticals (London, UK) appointed Ludovic Fenaux asSenior Vice President, International Commercial Operations with responsibility for commercial activities outside of the U.S. and Canada. // Next-generation Antibody Drug Conjugate development company Glythera Limited (Newcastle, UK) announced that it has changed its name to Iksuda Therapeutics.

update my profile / advertise with us / print subscribe / digital subscribe / visit pharmexec.com